Dataset Information

Epigenomic Profiling of Primary Gastric Adenocarcinoma Reveals Super-enhancer Heterogeneity [methylation]

ABSTRACT: Regulatory elements in cancer remain poorly characterized in primary solid tumors. Here we applied microscale histone modification profiling to delineate the landscape of somatic promoters and super-enhancers in primary gastric adenocarcinoma, analyzing 94 epigenomic profiles of primary tumors, normal tissues, and cell lines Overall design: DNA methylation profiles of 19 T/N pairs

INSTRUMENT(S): Illumina HumanMethylation450 BeadChip (HumanMethylation450_15017482)

SUBMITTER: Aditi Qamra

PROVIDER: GSE85464 | GEO | 2016-09-28

SECONDARY ACCESSION(S): PRJNA338608

REPOSITORIES: GEO

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	GSE85464_RAW.tar	Raw
	filelist.txt	Txt

Items per page:

1 - 2 of 2

Publications

Epigenomic profiling of primary gastric adenocarcinoma reveals super-enhancer heterogeneity.

Ooi Wen Fong WF Xing Manjie M Xu Chang C Yao Xiaosai X Ramlee Muhammad Khairul MK Lim Mei Chee MC Cao Fan F Lim Kevin K Babu Deepak D Poon Lai-Fong LF Lin Suling Joyce J Qamra Aditi A Irwanto Astrid A Qu Zhengzhong James J Nandi Tannistha T Lee-Lim Ai Ping AP Chan Yang Sun YS Tay Su Ting ST Lee Ming Hui MH Davies James O J JO Wong Wai Keong WK Soo Khee Chee KC Chan Weng Hoong WH Ong Hock Soo HS Chow Pierce P Wong Chow Yin CY Rha Sun Young SY Liu Jianjun J Hillmer Axel M AM Hughes Jim R JR Rozen Steve S Teh Bin Tean BT Fullwood Melissa Jane MJ Li Shang S Tan Patrick P

Nature communications 20160928

Regulatory enhancer elements in solid tumours remain poorly characterized. Here we apply micro-scale chromatin profiling to survey the distal enhancer landscape of primary gastric adenocarcinoma (GC), a leading cause of global cancer mortality. Integrating 110 epigenomic profiles from primary GCs, normal gastric tissues and cell lines, we highlight 36,973 predicted enhancers and 3,759 predicted super-enhancers respectively. Cell-line-defined super-enhancers can be subclassified by their somatic ...[more]

PMID: 27677335

Similar Datasets

Project description:Gastroesophageal adenocarcinoma (GEA) is a lethal disease where targeted therapies, even when guided by genomic biomarkers, have had limited efficacy. A potential reason for the failure of such therapies is that genomic profiling results could commonly differ between the primary and metastatic tumors. To evaluate genomic heterogeneity, we sequenced paired primary GEA and synchronous metastatic lesions across multiple cohorts, finding extensive differences in genomic alterations, including discrepancies in potentially clinically relevant alterations. Multiregion sequencing showed significant discrepancy within the primary tumor (PT) and between the PT and disseminated disease, with oncogene amplification profiles commonly discordant. In addition, a pilot analysis of cell-free DNA (cfDNA) sequencing demonstrated the feasibility of detecting genomic amplifications not detected in PT sampling. Lastly, we profiled paired primary tumors, metastatic tumors, and cfDNA from patients enrolled in the personalized antibodies for GEA (PANGEA) trial of targeted therapies in GEA and found that genomic biomarkers were recurrently discrepant between the PT and untreated metastases. Divergent primary and metastatic tissue profiling led to treatment reassignment in 32% (9/28) of patients. In discordant primary and metastatic lesions, we found 87.5% concordance for targetable alterations in metastatic tissue and cfDNA, suggesting the potential for cfDNA profiling to enhance selection of therapy.Significance: We demonstrate frequent baseline heterogeneity in targetable genomic alterations in GEA, indicating that current tissue sampling practices for biomarker testing do not effectively guide precision medicine in this disease and that routine profiling of metastatic lesions and/or cfDNA should be systematically evaluated. Cancer Discov; 8(1); 37-48. ©2017 AACR.See related commentary by Sundar and Tan, p. 14See related article by Janjigian et al., p. 49This article is highlighted in the In This Issue feature, p. 1.